Ad-hoc | 21 December 2005 14:28

STRATEC raises sales and earnings forecasts

Ad hoc announcement transmitted by DGAP. The issuer is solely responsible for the content of this announcement. —————————————————————————— STRATEC raises sales and earnings forecasts Birkenfeld, December 21, 2005 The Board of Management of STRATEC Biomedical Systems AG, listed in the German Prime Standard and in Gate-M, hereby announces the increase of its sales and earnings forecasts for the 2006 financial year pursuant to Section 15 of the German Securities Trading Act (WpHG). The company expects to be able to increase its sales for the 2006 financial year to between Euro 55 million and Euro 59 million (sales corridor). The median value of such range would then exceed the company’s most recently forecast target by around Euro 5 million. Earnings before tax (EBT) are expected to amount to between Euro 8.3 million and Euro 9.2 million in the 2006 financial year (earnings corridor). The median value of such range would then exceed the company’s previous forecast by around Euro 2.5 million. The company’s long-term profitability target of achieving an EBT margin of more than 15% would thus already be achieved in the 2006 financial year. The forecast for earnings before tax (EBT) for the 2006 financial year is based on the assumption of balanced net financial expenses. This ad hoc announcement (statutory company announcement) contains forward- looking statements based on current assumptions and forecasts made by the management of the STRATEC Group. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. STRATEC Biomedical Systems AG Gewerbestraße 37 75217 Birkenfeld Deutschland ISIN: DE0007289001 WKN: 728900 Listed: Geregelter Markt in Frankfurt (Prime Standard) und Stuttgart (Gate-M); Freiverkehr in Berlin-Bremen, Düsseldorf und München End of ad hoc announcement (c)DGAP 21.12.2005 Issuer’s information/explanatory remarks concerning this ad hoc announcement: This sales and earnings forecast was compiled on the basis of serial analyzer systems which are already available, in development and/or in the specification stage. A long-term sales and earnings forecast going beyond the 2006 financial year will be published by the company today in a separate press release. The preliminary figures for the 2005 financial year are expected to be published at the end of March 2006. About STRATEC STRATEC Biomedical Systems AG (http://www.stratec-biomedical.de) designs and manufactures fully automated systems for its partners in the fields of clinical diagnostics and biotechnology. These partners market such systems, in general together with their own reagents, to laboratories and research institutes around the world. The company develops its products on the basis of its own patented technologies. Shares in the company (WKN: 728900 / ISIN: DE0007289001) are traded in the Prime Standard segment of the Frankfurt Stock Exchange, in the Gate-M trading segment of the Stuttgart Stock Exchange and on other exchanges. The STRATEC Group comprises the listed holding company “STRATEC Biomedical Systems AG”, as well as the wholly-owned subsidiaries “STRATEC NewGen GmbH” and “Robion AG”. Further information can be obtained from: STRATEC Biomedical Systems AG André Loy, Investor Relations Gewerbestrasse 37, 75217 Birkenfeld Tel: +49 (0)7082 7916-190 Fax: +49 (0)7082 7916-999 E-mail: ir@stratec-biomedical.de End of message (c)DGAP